Anti-DLL3 antibodies and methods of use

A protein binding construct comprising a DLL3-binding domain that is capable of specifically binding DLL3 or an epitope of DLL3 comprising a heavy chain variable region (VH) comprising a complementarity determining region (CDR) 1, a CDR2, and a CDR3, wherein the CDR1, CDR2, and CDR3 comprise the amino acid sequences as set forth in any one of the following sets of SEQ ID NOs:

• a) SEQ ID NOs:
• 46, 47, and 48, respectively;
• b) SEQ ID NOs:
• 52, 53, and 54, respectively;
• c) SEQ ID NOs:
• 18, 19, and 20, respectively;
• d) SEQ ID NOs:
• 83, 2, and 84, respectively;
• e) SEQ ID NOs:
• 60, 61, and 62, respectively;
• f) SEQ ID NOs:
• 65, 66, and 67, respectively;
• g) SEQ ID NOs:
• 69, 23, and 24, respectively;
• h) SEQ ID NOs:
• 14, 43, and 71, respectively;
• i) SEQ ID NOs:
• 73, 74, and 75, respectively;
• j) SEQ ID NOs:
• 77, 78, and 79, respectively;
• k) SEQ ID NOs:
• 1, 2, and 3, respectively;
• l) SEQ ID NOs:
• 6, 7, and 8, respectively;
• m) SEQ ID NOs:
• 10, 11, and 12, respectively;
• n) SEQ ID NOs:
• 14, 15, and 16, respectively;
• o) SEQ ID NOs:
• 22, 23, and 24, respectively;
• p) SEQ ID NOs:
• 26, 27, and 28, respectively;
• g) SEQ ID NOs:
• 30, 2, and 31, respectively;
• r) SEQ ID NOs:
• 33, 81, and 34, respectively;
• S) SEQ ID NOs:
• 36, 82, and 37, respectively;
• t) SEQ ID NOs:
• 39, 40, and 41, respectively;
• and
• u) SEQ ID NOs:
• 14, 43, and 44, respectively.